Edwards Lifesciences Corporation (ETR:EWL)

Market Cap	37.19B
Revenue (ttm)	4.84B
Net Income (ttm)	3.53B
Shares Out	n/a
EPS (ttm)	5.97
PE Ratio	10.53
Forward PE	29.04
Dividend	n/a
Ex-Dividend Date	n/a

Volume	400
Average Volume	121
Open	62.98
Previous Close	63.63
Day's Range	62.40 - 63.00
52-Week Range	58.18 - 73.62
Beta	n/a
RSI	31.80
Earnings Date	Oct 24, 2025

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solution...

• Industry: Orthopedic, Prosthetic, and Surgical Appliances and Supplies
• Founded: 1958
• Employees: 15,800
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: EWL

Financial Performance

In 2024, Edwards Lifesciences's revenue was $5.44 billion, an increase of 8.57% compared to the previous year's $5.01 billion. Earnings were $4.17 billion, an increase of 197.68%.

Financial numbers in USD